CN109715157A - 用于治疗癌症的组合 - Google Patents

用于治疗癌症的组合 Download PDF

Info

Publication number
CN109715157A
CN109715157A CN201780056350.1A CN201780056350A CN109715157A CN 109715157 A CN109715157 A CN 109715157A CN 201780056350 A CN201780056350 A CN 201780056350A CN 109715157 A CN109715157 A CN 109715157A
Authority
CN
China
Prior art keywords
cancer
agent
carcinoma
subject
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780056350.1A
Other languages
English (en)
Chinese (zh)
Inventor
埃里克·桑托斯·马丁
横山由美
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ignyta Inc
Original Assignee
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc filed Critical Ignyta Inc
Publication of CN109715157A publication Critical patent/CN109715157A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201780056350.1A 2016-08-24 2017-08-22 用于治疗癌症的组合 Pending CN109715157A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662379169P 2016-08-24 2016-08-24
US62/379,169 2016-08-24
US201762521176P 2017-06-16 2017-06-16
US62/521,176 2017-06-16
PCT/US2017/048075 WO2018039275A1 (en) 2016-08-24 2017-08-22 Combinations for the treatment of cancer

Publications (1)

Publication Number Publication Date
CN109715157A true CN109715157A (zh) 2019-05-03

Family

ID=61246270

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780056350.1A Pending CN109715157A (zh) 2016-08-24 2017-08-22 用于治疗癌症的组合

Country Status (5)

Country Link
US (1) US20190224200A1 (cg-RX-API-DMAC7.html)
EP (1) EP3503887A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019524851A (cg-RX-API-DMAC7.html)
CN (1) CN109715157A (cg-RX-API-DMAC7.html)
WO (1) WO2018039275A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1608378A1 (en) 2003-04-02 2005-12-28 Nexmed (Holdings), Inc. Prostaglandin compositions and their use for the treatment of vasospasm
US11247990B1 (en) 2017-12-07 2022-02-15 Array Biopharma Inc Bicyclic fused pyridine compounds as inhibitors of TAM kinases
US11946094B2 (en) * 2017-12-10 2024-04-02 Augusta University Research Institute, Inc. Combination therapies and methods of use thereof
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
WO2020124043A1 (en) * 2018-12-13 2020-06-18 Gordon Erlinda M Methods of exploiting oncogenic drivers along the human cyclin g1 pathway for cancer gene therapy
US20220089540A1 (en) * 2019-01-17 2022-03-24 Board Of Trustees Of Michigan State University Compositions and methods for immune modulation and treatment of cancer
EP4149483A4 (en) * 2020-05-15 2024-09-11 Fred Hutchinson Cancer Center COMPOSITIONS AND METHODS FOR IMPROVING CANCER IMMUNOTHERAPY
WO2021244551A1 (zh) * 2020-06-02 2021-12-09 正大天晴药业集团股份有限公司 c-Met激酶抑制剂和抗PD-L1抗体的联用药物组合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103958497A (zh) * 2011-11-14 2014-07-30 赛福伦公司 作为AXL和c-MET激酶抑制剂的尿嘧啶衍生物
US20150290194A1 (en) * 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Therapeutic uses of selected pyrimidine compounds with anti-mer tyrosine kinase activity
CN105085680A (zh) * 2014-05-23 2015-11-25 复旦大学 人源化抗PD-1及c-MET双特异性抗体及其制备方法和应用
WO2016054555A2 (en) * 2014-10-03 2016-04-07 Novartis Ag Combination therapies
CN105683197A (zh) * 2013-08-02 2016-06-15 亚尼塔公司 单独地或与其它试剂联合地使用AXL/cMET抑制剂治疗多种癌症的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2763429T5 (es) * 2013-12-17 2023-06-21 Hoffmann La Roche Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
RS63364B1 (sr) * 2014-08-11 2022-07-29 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora
EP3233902B1 (en) * 2014-12-18 2020-09-09 Aravive Biologics, Inc. Antifibrotic activity of gas6 inhibitor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103958497A (zh) * 2011-11-14 2014-07-30 赛福伦公司 作为AXL和c-MET激酶抑制剂的尿嘧啶衍生物
CN105683197A (zh) * 2013-08-02 2016-06-15 亚尼塔公司 单独地或与其它试剂联合地使用AXL/cMET抑制剂治疗多种癌症的方法
US20150290194A1 (en) * 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Therapeutic uses of selected pyrimidine compounds with anti-mer tyrosine kinase activity
CN105085680A (zh) * 2014-05-23 2015-11-25 复旦大学 人源化抗PD-1及c-MET双特异性抗体及其制备方法和应用
WO2016054555A2 (en) * 2014-10-03 2016-04-07 Novartis Ag Combination therapies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
S MIKNYOCAKI 等: "ABSTRACT C275:CEP-40783: A POTENT AND SELECTIVE AXL/C-MET INHIBITOR FOR USE IN BREAST,NON-SAMLL CELL LUNG(NACLC),AND PANCREATIC CANCERS", 《MOLECULAR CENCER THERAPEUTICS》 *
YUMI YOKOYAMA 等: "Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor", 《CANCER RESEARCH》 *
叶因涛 等: "PD-1/PD-L1抑制剂在肿瘤免疫治疗中的研究进展", 《中国肿瘤临床》 *

Also Published As

Publication number Publication date
JP2019524851A (ja) 2019-09-05
EP3503887A4 (en) 2020-05-06
EP3503887A1 (en) 2019-07-03
US20190224200A1 (en) 2019-07-25
WO2018039275A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
CN109689056A (zh) 用于治疗癌症的组合
ES2856231T3 (es) Compuestos para el tratamiento de pacientes con células cancerosas con ROS1 mutante
DK2694072T3 (en) COMBINATION OF ACT-INHIBITOR RELATIONSHIP AND ABIRATERON FOR USE IN THERAPEUTIC TREATMENTS
JP2021523186A (ja) 抗がん核内ホルモン受容体標的化化合物
TW202131930A (zh) 抗癌核荷爾蒙受體標靶化合物
EP3697767B1 (en) Compounds and methods for treating cancer
JP2019524851A (ja) がんを治療するための組み合わせ
CN111225662B (zh) 药物组合物和剂型
CN109640988A (zh) Cxcr4抑制剂及其用途
KR20200031115A (ko) 엔트렉티닙을 포함하는 약학적 조성물
CN109982701A (zh) SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途
JP2019536790A (ja) がん治療のための方法
US10266490B2 (en) Radioprotector compounds
CN104837814B (zh) 新型化合物及其用途
JP2022545387A (ja) がんの処置方法
KR20130130802A (ko) 보르트만닌 유사체의 결정질 형태의 조성물 및 이의 사용 방법
WO2021046178A1 (en) Compounds and methods for treating cancer
BR122025029354A2 (pt) Método para preparar composição farmacêutica
HK40007858A (zh) 用於治疗癌症的组合
HK40069081A (en) Methods of treating cancer
HK40031775B (en) Compounds and methods for treating cancer
HK40031775A (en) Compounds and methods for treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40007858

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190503

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40007858

Country of ref document: HK